Evidence map›Paper›PMID 39998308›Full record

ArticleThe Biochemical journal2025

Effect of methyl DNA adducts on 3'-5' exonuclease activity of human TREX1.

Nikhil Tuti, Unnikrishnan P Shaji, Susmita Das, Roy Anindya

Abstract read
In one paragraph

Article in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nikhil TutiDepartment of Biotechnology, Indian Institute of Technology Hyderabad (IITH), Telangana, Kandi, Sanga Reddy 502284, India.
Unnikrishnan P ShajiDepartment of Biotechnology, Indian Institute of Technology Hyderabad (IITH), Telangana, Kandi, Sanga Reddy 502284, India.
Susmita DasDepartment of Biotechnology, Indian Institute of Technology Hyderabad (IITH), Telangana, Kandi, Sanga Reddy 502284, India.
Roy AnindyaDepartment of Biotechnology, Indian Institute of Technology Hyderabad (IITH), Telangana, Kandi, Sanga Reddy 502284, India.ORCID 0000-0001-8561-907X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-prime repair exonuclease 1 (TREX1) is a 3'-5' exonuclease that plays an important role in clearing cytoplasmic DNA. Additionally, TREX1 is translocated to the nucleus after DNA damage and assists in DNA repair. In this work, we evaluated the activity of TREX1 in the context of the removal of methyl DNA adducts. We observed that TREX1 was less efficient at degrading methyl methanesulfonate (MMS)-treated methylated DNA compared with normal DNA. Two methyl DNA adducts, N1-methyladenine and N3-methylcytosine, were found to block TREX1 exonuclease activity. To understand the mechanism of limited TREX1-mediated degradation of MMS-damaged DNA, stem-loop substrates containing solitary methyl adducts were prepared. We found that when the solitary methyl adducts were present at the 3'-terminal single-stranded overhang, it prevented degradation by TREX1. However, TREX1 could efficiently process internally located duplex DNA methyl adducts when the 3'-terminal of the scissile strand was damage-free. Broadly, these observations suggest that TREX1 may be capable of resecting methyl adducts containing DNA, but it might be less proficient of removing 3'-terminal DNA methyl adducts.

Indexed as

DNA AdductsDNA MethylationExodeoxyribonucleasesPhosphoproteinsDNA RepairHumansMethyl MethanesulfonateDNA AdductsExodeoxyribonucleasesMethyl MethanesulfonatePhosphoproteinsthree prime repair exonuclease 11-methyladenine3-methylcytosineDNA damageexonucleaseTREX1

Identifiers

PMID39998308
PMCPMC12133304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.